-

09:29:41 PM

RVVTF Stock News

RVVTF - Revive Therapeutics Ltd

11/30/22 5:43 PM

OTC : RVVTF

Revive Therapeutics Ltd. Announces Offering of Up to $5 Million

REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQB: RVVTF) (“ Revive ” or the “ Company ”) is pleased to announce that it is arranging a private placement of a minimum of $3 million and up to $5 million of units (each, a “ Unit ”), at a price of $0.15 per Unit;

RHEA-AI

neutral

11/24/22 9:18 AM

OTC : RVVTF

clinical trialcovid-19

Revive Therapeutics Announces Update for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it will

RHEA-AI

neutral

11/22/22 9:20 AM

OTC : RVVTF

clinical trialcovid-19

Revive Therapeutics Announces FDA Recommendation for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that the U.S.

RHEA-AI

neutral

10/14/22 1:34 PM

OTC : RVVTF

clinical trialcovid-19

Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has

RHEA-AI

neutral

09/28/22 7:00 AM

OTC : RVVTF

clinical trialcovid-19

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced an update on

RHEA-AI

neutral

09/16/22 6:00 AM

OTC : RVVTF

clinical trial

Revive Therapeutics Provides Update on the Psilocybin Clinical Study for Methamphetamine Use Disorder and Oral Psilocybin Thin Film Strip Program

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an

RHEA-AI

neutral

09/14/22 6:00 AM

OTC : RVVTF

clinical trialcovid-19

Revive Therapeutics Announces Submission of Amended Phase 3 COVID-19 Study Protocol to FDA

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has

RHEA-AI

neutral

08/16/22 6:00 AM

OTC : RVVTF

clinical trialcovid-19

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an

RHEA-AI

neutral

07/25/22 10:57 AM

OTC : RVVTF

clinical trialcovid-19

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an

RHEA-AI

neutral

06/24/22 11:41 AM

OTC : RVVTF

clinical trialcovid-19

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company

RHEA-AI

neutral